history – Page 18 – Communicable Diseases Research

Endoneural abscess of common popliteal nerve as first clinical manifestation of leprosy: the first reported case in history in a low-incidence country

말초신경의 첫 번째 임상 증상으로서의 일반 비골 신경의 내신경 농양: 저발병률 국가에서 보고된 첫 번째 사례

Article

Published on 2020-07-042024-08-24
Journal: J Prev Med Hyg [Category] 한센병,

Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial

Letter

Published on 2020-07-022022-10-29
Journal: Trials [Category] COVID-19, SARS,

[키워드] 1:1 aetiology agreement allocation Anosmia anticipated Arm ARMS Asymptomatic automatically Barcelona blinded block randomization Cardiac pathology change characterized chills clinical Clinical course clinical trial close contact collected Compound Concomitant conducted confirmed COVID-19 case Contact cough Course COVID-19 COVID-19 disease COVID-19 disease severity CRF criteria delivery determine diarrhoea dissemination double-blind Dyspnoea ECDC Effect Efficacy Efficacy and safety element EudraCT evaluate evaluate the effect Fever FIVE gestation global health HCQ headache history hospital Hospitalization Hydroxychloroquine hypersensitivity inclusion criteria intervention study investigator Liver disease Mild mild symptoms Mortality multicentre nasopharyngeal number objective oropharyngeal swab outcome packaged Pain participant Patient PCR PCR-confirmed Placebo placebo controlled trial placebo-controlled Pregnancy pregnant pregnant women prenatal Prevent Primary outcome progression protocol randomised randomised controlled trial Randomized receive recruited recruitment reducing Registered risk Sample size SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 PCR SARS-CoV-2 viral shedding status stratified study group study participant Study protocol subsequent Symptom symptomatic syndrome Tablet Tolerability Transmission Treatment treatment group Trial Two-arm uterine website women
[DOI] 10.1186/s13063-020-04557-y PMC 바로가기 [Article Type] Letter

A prospective, randomized, controlled study assessing vagus nerve stimulation using the gammaCore®-Sapphire device for patients with moderate to severe CoViD-19 Respiratory Symptoms (SAVIOR): A structured summary of a study protocol for a randomised controlled trial”

Letter

Published on 2020-06-262022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 Acute respiratory failure Administered Admission Adverse age Aneurysm Antibiotics atherosclerotic baseline blind blood pressure Brain cardiovascular disease carotid cerebrovascular accident cervical spine chronic clinical trial Complete congestive heart failure Consent control group Controlled trial Coronary artery disease cough COVID-19 criteria current cytokine Cytokine storm Day decrease Delay Disabled disease dissemination distress dose electrical element eligible enrolled evaluate expected Follow-up Gender growth Healthcare provider hemorrhage history hospital hospital discharge ICU admission Informed Initiation interleukin interleukin 6 Intervention less mechanical ventilation mechanical ventilator Mild moderate Mortality Myocardial infarction nerve stimulation number O2 Saturation objective occur Older open label outcome oxygen Oxygen level Oxygen therapy parallel group participant Patient patients with moderate per day persist positive prophylactically protocol pulmonary randomisation randomised randomised controlled randomised controlled trial randomization Randomized recruited recruitment reduce reduction regimen Registered required Research respiratory Respiratory failure Sample size Sapphire saturation second dose secondary severity Shortness of breath SOC Spain Standard Standard of care status storm stratified study group Study protocol subject supplemental oxygen supplemental oxygen requirement tested trauma Treatment tumor necrosis factor tumors uncontrolled Vague neurostimulation Valencia Ventilation ventilatory support website women
[DOI] 10.1186/s13063-020-04486-w PMC 바로가기 [Article Type] Letter

Randomised controlled trial comparing efficacy and safety of high versus low Low-Molecular Weight Heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): a structured summary of a study protocol

Letter

Published on 2020-06-262022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 24 hour Administered airway allocation concealment Alpha ambient analysed aneurysms Anticoagulant treatment anticoagulation antiplatelet Arm arterial assigned Atrial fibrillation bleeding bleeding event block size Blood BMI Body Breastfeeding breath calculated Cancer clinical clinically Coagulopathy Concomitant conjunctival Continuous contributed Control control group Controlled trial corpus COVID-19 COVID19 criteria Critical D-dimer D-dimer level Day death defined detect diagnostic discharged disease severity dissemination dosage dose effective Efficacy and safety element enoxaparin Epistaxis EudraCT event events expected fibrinogen level gingival bleeding group Haemoglobin haemoptysis health-care hematemesis hematoma hemodynamic heparin High dose high risk history hospital discharge Hospital stay hospitalized patient hypersensitivity Hypothesis IL-6 Impaired impairing improvement IMV In-hospital indication initiated Inpatient INR internal Intervention intervention group Intra-articular intramuscular invasive Invasive mechanical ventilation involved Italian Italy laboratory parameter LMWH low dose low-molecular weight heparin macroscopic Major major bleeding management Mechanical mechanical ventilation medical intervention Medicine Modena NIV Non-invasive number objective occur Occurrence open label ophthalmic oral anticoagulant outcome oxygen paO2/fiO2 parallel group participant pathology Patient performed Pharyngeal swab plasma Platelet Pneumonia positive pregnancy test Presence pressure Primary outcome prophylactic dose prosthetic protocol random randomisation randomised randomised controlled randomised controlled trial randomization Rate receiving recorded recruited Rectal Bleeding reduce reduction in Registered renal function reported required respiratory risk risk of death Sample size SARS-CoV-2 secondary secure Severe COVID-19 pneumonia severe disease significantly Spontaneous standard oxygen therapy Stata status stratified stroke study drug Study protocol subcutaneously surgical susceptible symptomatic syndrome therapeutic dose therapy thrombocytopenia time transfusion Treatment unfractionated heparin unit Vascular venipuncture Venous Thromboembolism web-based system website weight Withdrawal worsening
[DOI] 10.1186/s13063-020-04475-z PMC 바로가기 [Article Type] Letter

Efficacy and safety of Anluohuaxian in the treatment of patients with severe Coronavirus disease 2019- a multicenter, open label, randomized controlled study: a structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-06-082022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 6-minute walking distance actual Alpha analyst Anluohuaxian antiviral drugs brand bronchial asthma Care change changes Chinese Chinese herbal medicines chronic obstructive Colchicine Combined completion Compliance composed computer tomography Confirmed connective tissue control group Coronavirus disease 2019 COVID-19 criteria Cyclophosphamide cytokine diagnosed dissemination distribution drug Efficacy and safety element Endocrine enrolled Estimated evaluate expected experimental group explained facilitate fibrosis glucocorticoid groups hepatic fibrosis High-resolution history Hormones HRCT Huoshenshan Hospital Imatinib include indicate interferon-γ interstitial Interstitial lung disease investigators involved IWRS Kidney disease lactating liver lobular lung maximum Mental Disorders minimum multicenter Nasopharyngeal swab Necrosis negative neurologic Nintedanib nodule not blinded nucleic acid test number objective open label outcome outcome assessors participant Participants Pathogenesis pathway Patient pharmaceutical pill professional proportion protocol provided pulmonary pulmonary disease pulmonary fibrosis random randomised randomised controlled trial randomization randomization system Randomized Randomized controlled trial randomly divided RCT recruitment Research research drug respiratory specimen Sample size Science second selected severe COVID-19 sputum statistical status Study protocol subject technology therapeutic drug Tongji Hospital treated Treatment treatment group Trial Union Hospital university variety website West Wuhan Year
[DOI] 10.1186/s13063-020-04399-8 PMC 바로가기 [Article Type] Letter

The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial

Letter

Published on 2020-06-082022-10-29
Journal: Trials [Category] COVID-19, SARS,

[키워드] 1:1 48 hour 48 hours Activation Administered adverse event African age allergy analyzed Angola Antiviral approved ARMS Barcelona baseline blinded block Cerebrovascular disease chain chest X-ray childbearing chronic clinical care clinical trial co-morbidity conducted contraceptive method control group coronary disease cough country COVID-19 COVID-19 disease COVID-19 patient criteria Critical current CYP3A4 death detectable determine diagnosed with COVID-19 disease dissemination dose double-blind drug early treatment Efficacy element Endemic EudraCT excluded eye Factor Fever flow cytometry Follow-up visit Frequency Gabon global health groups history home visit Identified IgA IgA level IgG IgM immune response Immunity immunology immunomodulatory IMPROVE in vivo Infection Inflammatory inhibitor interfere investigator involved Isolation Ivermectin laboratory parameter Loa loa magnitude marker median Nasopharyngeal swab nasopharyngeal swab PCR negative neoplasm Nigeria no risk number objective outcome participant Patient Patient care patients PCR PCR cycle physical Placebo placebo group placebo-controlled Pneumonia positive positive SARS-CoV-2 PCR post-menopausal Potential pregnancy test pregnant women progression proportion protocol public health pulmonary random randomised randomised controlled trial randomization randomization list Randomized Rapid diagnostic test reaction receive recent recruited reduce Registered renal resident risk Ritonavir Safe Sample size SARS-CoV-2 SARS-CoV-2 RNA SARS-CoV-2-specific T cell secondary sequence Seroconversion severe disease severity single center single dose Spain status Study protocol subject submitted surgical Symptom symptom onset the patient the SARS-CoV-2 threshold transcriptomics Transmission transmission-blocking Travel treated patient treated patients Treatment treatment group Trial unblinding Viral load virus vulnerable population website with mild disease women
[DOI] 10.1186/s13063-020-04421-z PMC 바로가기 [Article Type] Letter

Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-06-052022-10-29
Journal: Trials [Category] COVID-19, SARS,

[키워드] 1:1 7-point ordinal scale accelerate activities activity acute respiratory syndrome adaptive addition administration Admission airway Akershus allocation sequence Analysis anticipated approach automatically baseline Biochemistry Biomarker blinded Blinding Blood C-reactive protein cardiac troponin Chloroquine clinical Clinical outcome Clinical practice clinical status clinical symptom collected condition coronavirus coronavirus disease COVID-19 Culture database Department disease dissemination early treatment element Endpoint examined excluded extracorporeal membrane oxygenation Good harmonization hepatic injury history hospital Hospital admission hospitalisation hospitalised hospitalised patient Hospitalized Hydroxychloroquine Hypothesis In-hospital include independent Inpatient intensive care intensive care unit International Conference Intervention intervention arm Invasive mechanical ventilation Laboratory marker Microbiology Mortality nasopharyngeal NEWS2 non-invasive ventilation Norway number Nurse objective open label Oropharyngeal Oropharyngeal sampling outcome oxygen participant Patient patients peptide Placebo polymerase chain polymerase chain reaction positive Practice Pragmatic pragmatic trial primary endpoint profile Prolonged Protein protocol QT interval randomisation randomised randomised controlled randomised controlled trial randomization Randomized Randomized controlled trial recruited recruitment Registered renal requiring supplemental oxygen resource responsible RT-PCR Safe Sample size SARS-CoV-2 SARS-CoV-2 viral load score secondary Seven standard care statistical analyses status Study protocol subjects Surveillance therapy transcriptase Treatment treatment allocation Trial Two-arm university use of hydroxychloroquine Viral load virological clearance viruses vital signs website
[DOI] 10.1186/s13063-020-04420-0 PMC 바로가기 [Article Type] Letter

The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-06-052022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 24 hours acid Administered Affect analyst Anti-viral anticipated Beijing block block randomization Blood Body Capital cardiovascular system Care center changed Chinese clinical clinical manifestation Clinical outcome Clinical studies clinical trial college Complete condition Consent control group Corona Corona virus cough COVID-19 criteria curative Diagnosis discharge discharged disease Diseases dissemination dose drug Ebola virus element eligibility criteria enrolled expected experimental group Favipiravir female Follow-up form hepatology history hospital include Including Infection Infectious disease Informed inhibit investigators kidney lack lactating women life-threatening liver Loss male Measures mechanism Medicine Mental Disorders Nasopharyngeal swab nasopharyngeal swabs not blinded nucleic acid nucleic acid test number objective open label oral administration outcome outcome assessors Oxygen therapy parallel group participant Participants Patient plan poor compliance positive protocol Public pulmonary randomised randomised controlled trial randomization system Randomized controlled trial Randomly recruited recruitment reduced Regular Reinfection Research researcher respiratory specimen response returned RNA-dependent RNA polymerase routine screening visit second secondary severe adverse events severity severity of symptoms Shenzhen specimens sputum status Study protocol subject Symptom Symptoms System temperature Test tested therapeutic efficacy throat swabs Traditional Treatment treatment for COVID-19 treatment group Trial uncontrolled university variety viral nucleic acid virus Web website Withdrawal Wuhan
[DOI] 10.1186/s13063-020-04430-y PMC 바로가기 [Article Type] Letter

A randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts (MeCOVID Trial): A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-06-032022-10-29
Journal: Trials [Category] COVID-19, SARS,

[키워드] 1:1 age analogue anticipated assigned Asymptomatic blinded bpm Characteristics clinical trial comparator components Contact Controlled trial coronavirus disease COVID-19 COVID-19 symptom COVID19 Date deficiency develop Diabetes Mellitus Diagnosis disease dissemination dose double-blind drug Efficacy Efficiency eight element enrolled enrolment EU Clinical Trial evaluate evaluate the effect exclusion criteria experimental arm female participant Final Glucose haloperidol healthcare healthcare worker Healthcare workers hematological Hemodialysis hepatitis B Hereditary high risk history HIV HIV infection hospital hypersensitivity IgM/IgG immune immunosuppressive incidence Inclusion Infection Inflammatory cytokine Intervention less lymphopenia male melatonin men and women multicenter myasthenia gravis number objective outcome participant Patient PCR Placebo polymerase chain post-symptom onset Premenopausal Prevent prophylactic treatment Prophylaxis protocol Ramón randomisation randomised randomised controlled trial randomization Randomized Rapid test receiving recruited renal failure Research Retinitis rheumatoid arthritis risk RT-PCR Sample size SARS-CoV 2 SARS-CoV-2 SARS-COV-2 infection SAS version 9.4 secondary sequence Seroconversion severe COVID-19 severity of COVID-19 Sex Spain Spanish statistical status stratified study drug Study protocol symptomatic infection symptomatic SARS-CoV-2 infection Treatment Trial two-arm parallel ulcerative colitis understanding urinary pregnancy test Vasculitis website weight women
[DOI] 10.1186/s13063-020-04436-6 PMC 바로가기 [Article Type] Letter

Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-06-032022-10-29
Journal: Trials [Category] COVID-19, SARS,

[키워드] 1:1 access acute respiratory syndrome addition age anticipated assigned Asymptomatic Baltimore baseline blinded blocked Bone marrow Boston Care Chloroquine clinically suspected close contact Complete Compound Concomitant concomitant use conducted Contact coronavirus coronavirus disease cough COVID-19 criteria current Date defined determine Diagnosis disorder dissemination Efficacy element eligible eligible participant etiology excluded first dose HCQ Health care worker healthcare worker history Hospitalized household household contact Hydroxychloroquine hypersensitivity incidence index case Infection Intervention leukocyte Los Angele medication moderate multisite neutropenia New Orlean New York City number objective outcome participant PCR-confirmed Pharmacist polymerase chain polymorphonuclear Post-exposure prophylaxis Prevent Primary outcome prolonged exposure Prophylaxis protocol psoriasis randomised randomised controlled trial randomization Randomized receive receiving Registered registry renal impairment responders resulting Sample size SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 PCR test Seattle Secondary objective Seven severe liver disease Shortness of breath statistical statistician stratified study drug study period Study protocol subjective fever syndrome Tamoxifen telehealth therapy Tolerability Treatment Trial Vaccine virus website women
[DOI] 10.1186/s13063-020-04446-4 PMC 바로가기 [Article Type] Letter